Advertisement

Topics

Goldman's optimistic view of Alzheimer's drug lifts Biogen shares

07:05 EDT 17 Aug 2017 | thePharmaLetter

Goldman Sachs cited Biogen’s experimental Alzheimer’s drug aducanumab as a major reason for its addition…

Original Article: Goldman's optimistic view of Alzheimer's drug lifts Biogen shares

NEXT ARTICLE

More From BioPortfolio on "Goldman's optimistic view of Alzheimer's drug lifts Biogen shares"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...